Aug 12, 2020
Resoundant Expands Its Research Services Footprint
May 24, 2020
HistoIndex's AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China
May 07, 2020
Galmed Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Business Update on Thursday May 14
Mar 05, 2020
Zydus Announces World's First Drug for the Treatment of Non-Cirrhotic NASH
Mar 05, 2020
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results and Provide Business Update on Thursday March 12
Mar 03, 2020
MAX BioPharma Announces Key Update to its Liver Fibrosis Program Showing Efficacy of an Oxysterol Lead Drug Candidate in Inhibiting NASH in a Humanized Mouse Model
Feb 25, 2020
Clinical Study Supports Bergacyn® for Liver and Vascular Health
Jan 13, 2020
Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients
Oct 31, 2019
Pliant Therapeutics to Present Preclinical Data in Primary Sclerosing Cholangitis at The Liver Meeting 2019
Oct 30, 2019
PharmaNest Announces New Adult and Pediatric NASH Data to Be Presented at the AASLD - Liver Meeting® 2019
Oct 30, 2019
Galmed Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on Wednesday, November 6
Oct 16, 2019
Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH
Oct 03, 2019
Akero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero's 3D InSight(TM) Human Liver Disease platform
Oct 03, 2019
Zydus Announces Positive Results From EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NAFLD and NASH
Sep 30, 2019
Ascletis Announces Departure of Chief Financial Officer
Sep 24, 2019
PharmaNest Launches FibroNest, the First Multivendor Image Analysis and Translational Platform for the Assessment of the Severity and Progression of Fibrosis in NASH
Aug 28, 2019
FDA In Brief: FDA warns patients and health care professionals about rare instances of serious liver injury or failure with certain hepatitis C treatments in some patients with advanced liver disease
Aug 27, 2019
Ascletis Received IND Approval for its NASH Drug
Aug 12, 2019
Ascletis Opens Clinical Development Shanghai Center
Aug 05, 2019
3-V Biosciences Changes Name to Sagimet Biosciences and Closes $25 Million Financing